CompletedNCT03056482
Haloperidol Compared With Ondansetron for Cannabis-Related Vomiting
About this title
Read the official source — NCT03056482Medication studyAges 18–100CanadaAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 100 years.
- Listed locations
- Kingston and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: May 21, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 33
- Sponsor
- Dr. Marco L.A. Sivilotti
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- From 18 Years to 100 Years
- Official registry ID
- NCT03056482
- Official title
Show the full official title
Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Kingston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Dr. Marco L.A. Sivilotti.
Did this study involve medication?
Yes. The study involved medication, including Ondansetron 8mg, Haloperidol 0.05mg/kg and Haloperidol 0.1mg/kg.
Who was this study for?
Listed age limits: 18 years to 100 years.
